

2015-11-06

**WntResearch hereby presents its interim report with Foxy-5 phase 1-data**

**The interim report can also be found on WntResearch homepage:  
[www.wntresearch.com](http://www.wntresearch.com)**

**For additional information please contact:**

Nils Brünner, CEO

E-mail: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)

Telephone: + 45 2614 4708

**About WntResearch**

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.